Clinical Trial

Hyperpolarized 13C-MRI and Radiomics in Rectal Cancer

Study acronym: DNP_RECA
Recruiting
View on ClinicalTrials.gov →
Summary
This study is testing new imaging and analysis methods to improve how doctors predict treatment response in rectal cancer patients receiving chemoradiotherapy. Current MRI scans sometimes miss complete tumor response, which can lead to unnecessary surgery. To address this, researchers will use a special MRI technique called hyperpolarized carbon-13 MRI, along with blood and tissue analysis (metabolomics) and advanced image feature analysis (radiomics). These tools can track how cancer cells use energy and how metabolism changes during treatment. The study will follow 30 rectal cancer patients at Chang Gung Memorial Hospital over 3 years. Patients will undergo standard MRI, colonoscopy, and advanced metabolic imaging before and after treatment. Results will compare patients whose tumors completely respond to therapy with those who do not. The goal is to see if metabolic changes detected by hyperpolarized MRI and metabolomics can predict treatment outcomes earlier and more accurately. This may help doctors avoid unnecessary surgery and provide more personalized care for rectal cancer patients.
Trial Details
NCT Number NCT07730541
Lead Sponsor Chang Gung Memorial Hospital
Collaborators: Ministry of Science and Technology, Taiwan
Conditions Neoadjuvant Chemoradiotherapy
Enrollment 30 participants
Start Date 2026-06-01
Primary Completion 2028-07-30 (estimated)
Study Completion 2028-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-28